Demographics, Prognostic Factors, and Survival Outcomes in Hepatic Angiosarcoma: A Retrospective Analysis
Journal of Gastrointestinal Cancer · 2025
DOI: 10.1007/s12029-024-01157-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gastrointestinal Cancer, 2025. Verfasst von Agha Wali und 10 weiteren Autor:innen. Beteiligte Einrichtung: Banner University Medical Center, Phoenix, AZ, USA. Hauptthemen laut MEDLINE: Hemangiosarcoma, Liver Neoplasms, SEER Program. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Hepatic angiosarcoma (HA) is a rare malignant vascular neoplasm. Currently, there are no standardized protocols for treating HA. This study aims to understand clinicopathologic analysis, prognostic factors, and treatment outcomes comprehensively. METHODS: The data retrieved from the SEER database was reviewed for hepatic angiosarcoma cases between 2000 and 2021. RESULTS: A total of 389 patients with hepatic angiosarcoma were identified with a mean age of 63.9 years (SD ± 16). Most patients were male (64%), and per US census data, non-Hispanic Asians or Pacific Islanders were the most common race (17%). In known cases of tumor stage (61%), the most common tumor stage was distant (22%), and most were grade III (18%) tumors. Overall, the 3-year survival rate was 6.7% with a 95% confidence interval (95% CI 0.044-0.100), disease-specific survival at a 1-year survival rate was 4.43% (95% CI 0.023-0.083), and no patients survived by 3 years. The best overall survival rate was the 1-year rate for surgical resection, 18.20% (95% CI 0.075-0.441). Chemotherapy had a 1-year survival rate of 11% (95% CI 0.057-0.211), and radiation therapy had no survival significance (p = 0.2). Multivariate analysis shows age above 70 years (H.R. 1.67 (95% CI 1.181-2.381), p 70 years), male sex, and distant stage were found to be strong predictors of poor survival outcomes. Patients had better outcomes when surgical resection and chemotherapy were included in their treatment. These results can provide continued evidence in the future management of patients with hepatic angiosarcoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Banner University Medical Center, Phoenix, AZ, USA.
- Texas Tech University Health Sciences Center, Lubbock, TX, USA.
- Department of Medicine, Northeastern Health System, Tahlequah, OK, USA.
- Department of GI Oncology, University of Florida Health Cancer Center, Gainesville, FL, USA.
- Department of Surgery, University of New Mexico, Albuquerque, NM, USA.
- All India Institute of Medical Sciences, Jodhpur, India.
Zitieren
APA
Wali, A., Robinson, J., Iqbal, A., Yasinzai, A. Q. K., Sohail, A. H., Jain, H., Fadhil, N., Khan, M., Khan, I., Karki, N. R., & Ullah, A. (2025). Demographics, Prognostic Factors, and Survival Outcomes in Hepatic Angiosarcoma: A Retrospective Analysis. Journal of Gastrointestinal Cancer. https://doi.org/10.1007/s12029-024-01157-w
Vancouver
Wali A, Robinson J, Iqbal A, Yasinzai AQK, Sohail AH, Jain H, et al. Demographics, Prognostic Factors, and Survival Outcomes in Hepatic Angiosarcoma: A Retrospective Analysis. Journal of Gastrointestinal Cancer. 2025. doi:10.1007/s12029-024-01157-w
BibTeX
@article{Wali2025,
author = {Wali, Agha and Robinson, Jaylyn and Iqbal, Asif and Yasinzai, Abdul Qahar Khan and Sohail, Amir Humza and Jain, Hritvik and Fadhil, Nooran and Khan, Marjan and Khan, Israr and Karki, Nabin R and Ullah, Asad},
title = {Demographics, Prognostic Factors, and Survival Outcomes in Hepatic Angiosarcoma: A Retrospective Analysis},
journal = {Journal of Gastrointestinal Cancer},
year = {2025},
doi = {10.1007/s12029-024-01157-w}
}
EUVIMED